Pegfilgrastim Biosimilar Market to Hit USD 3.66 Billion by 2033 | Coherus Biosciences, Mylan N.V., Biocon Lead - Fact.MR

As per Fact.MR's latest industry analysis, the global pegfilgrastim biosimilar market stands at US$ 1.41 billion in 2023. Global demand for pegfilgrastim biosimilars is projected to reach a market valuation of US$ 3.66 billion by 2033-end, increasing at a CAGR of 10% over the next ten years.This substantial growth is driven by the rising incidence of cancer worldwide, increasing adoption of chemotherapy treatments, and the demand for cost-effective biosimilars to manage chemotherapy-induced neutropenia. The market is benefiting from patent expirations of reference biologics like Neulasta, regulatory support for biosimilars, and innovations in drug delivery systems. North America remains the leading region, with strong demand in the United States due to favorable FDA policies. Globally, the market is shaped by the need for affordable oncology supportive care, biosimilar interchangeability, and advancements in formulations. However, challenges such as complex approval processes and patent litigation could impact growth, necessitating ongoing innovation to meet regulatory and patient demands.

Want a Sample Before Buying? Download Free Sample:https://www.factmr.com/connectus/sample?flag=S&rep_id=1494

Pegfilgrastim Biosimilar Market Technology Development:

Technological advancements are transforming the pegfilgrastim biosimilar market, emphasizing improved efficacy, patient convenience, and cost-efficiency. Pegfilgrastim, a PEGylated form of filgrastim, stimulates neutrophil production to combat neutropenia in cancer patients. Biosimilars replicate this with high similarity to the reference product, Neulasta, introduced by Amgen in 2002. Key innovations include advanced delivery devices like on-body injectors, which provide controlled, slow-release administration, reducing the need for multiple clinic visits. Extended-release formulations are also emerging, allowing less frequent dosing and enhancing adherence. Research into oral biosimilars, though in early stages, could revolutionize administration by eliminating injections. Biosimilar interchangeability, requiring rigorous clinical data, enables seamless switches between reference and biosimilar products without efficacy loss. These developments align with global sustainability trends, as biosimilars reduce healthcare costs while maintaining safety. Manufacturers like Novartis (Sandoz) and Pfizer are investing in bioengineering and analytical testing to meet stringent regulatory standards, positioning the market for accelerated growth through 2033.

Pegfilgrastim Biosimilar Market Demand and Impact Analysis:

Demand for pegfilgrastim biosimilars is surging due to the global cancer burden, with the World Health Organization reporting nearly 10 million cancer deaths in 2020 and rising incidences from lifestyle and environmental factors. Chemotherapy, a cornerstone of cancer treatment, often induces neutropenia, increasing infection risks and treatment disruptions. Pegfilgrastim biosimilars mitigate this by boosting neutrophil counts, serving as prophylactic measures post-chemotherapy. The market's growth is amplified by biosimilars' affordability-offering up to 30-40% cost savings compared to originators-making them accessible in resource-limited settings. Applications span chemotherapy treatment (holding the majority share) and transplantation, with hospital pharmacies dominating distribution due to centralized cancer care. Positive impacts include enhanced patient outcomes, reduced hospitalizations, and healthcare cost containment. However, restraints like lengthy approval processes, involving extensive similarity testing and potential patent disputes, delay market entry. Economic factors, such as raw material volatility, and regulatory evolution add uncertainty. Despite this, opportunities arise from aging populations in regions like Japan and biosimilar adoption in emerging markets, driving a 10% CAGR through 2033.

Pegfilgrastim Biosimilar Market Analysis by Top Investment Segments:

The pegfilgrastim biosimilar market is segmented by application (chemotherapy treatment, transplantation), distribution channel (hospital pharmacies, retail pharmacies, mail order/online pharmacies), and region (North America, Latin America, Europe, East Asia, South Asia & Oceania, MEA). Chemotherapy treatment is the most lucrative segment, projected to grow at over 10% CAGR from 2023 to 2033, driven by its dominance in cancer management and the need for neutropenia prophylaxis. This segment accounts for approximately 70% of the market, particularly in high-cancer-prevalence areas. Transplantation applications are gaining traction with rising organ and stem cell procedures. By distribution, hospital pharmacies lead with a 50-60% share, as they serve as hubs for oncology treatments, ensuring controlled administration. Retail and online channels are expanding due to patient convenience and e-pharmacy growth. Regionally, North America offers prime investment opportunities with its mature market and patent expirations. Emerging segments like innovative formulations (e.g., extended-release) represent high-return investments, especially in biosimilar-interchangeable products. Investors should focus on R&D for enhanced delivery and partnerships for market penetration, capitalizing on cost-saving biosimilars amid global cancer rises.

Pegfilgrastim Biosimilar Market Across Top Countries:

1.United States is a profitable hub, driven by biologics patent expirations and FDA's Biosimilar Action Plan, promoting competition and affordability. Market growth here is supported by high cancer rates and cost-containment efforts.

2.Germany excels with its early biosimilar adoption and emphasis on healthcare savings, where pegfilgrastim biosimilars reduce costs significantly in a regulated environment.

3.Japan's market is propelled by an aging population and increasing cancer incidence, with local firms partnering internationally to enhance biosimilar access.

India and China (part of South and East Asia), rapid urbanization and rising cancer cases boost demand, with governments encouraging biosimilar production for affordable care. India's market benefits from companies like Biocon and Zydus Cadila.
5.Europe, including the UK and France, sees steady growth from stringent regulations and biosimilar acceptance. These countries collectively drive over 40% of global demand, with Asia-Pacific emerging fastest due to population growth and healthcare investments.

Leading Pegfilgrastim Biosimilar Companies and Their Industry Share:

The pegfilgrastim biosimilar market is competitive, led by multinational firms with strong R&D and distribution networks. Key players include Coherus Biosciences, Mylan N.V. (now part of Viatris), Biocon, Novartis AG (Sandoz), Pfizer Inc., and others like Intas Pharmaceuticals, Zydus Cadila, Mundipharma, and Fresenius Kabi, holding significant shares. Coherus leads with Udenyca, capturing substantial U.S. market penetration through competitive pricing. Mylan and Biocon dominate via partnerships, such as their 2020 Fulphila collaboration, emphasizing affordable oncology biosimilars. Novartis (Sandoz) excels in Europe with Ziextenzo, leveraging regulatory expertise. Pfizer's Nyvepria adds to its portfolio strength. These companies engage in acquisitions-like Mundipharma's 2018 Cinfa Biotech buyout-and innovations to expand shares. Regional players like Green Cross Corp in Asia contribute to fragmentation, but leaders command 60-70% collectively through strategic alliances and patent challenges.

Pegfilgrastim Biosimilar Market Historic and Future Pathway Analysis:

Historically, the pegfilgrastim biosimilar market grew from niche launches post-Neulasta's 2002 introduction, with biosimilars entering after 2018 patent expirations. From 2018-2022, the market expanded at around 8-10% annually, driven by approvals in Europe and the U.S., reaching $1.41 billion by 2023. Shifts toward biosimilars reduced costs and improved access. Looking ahead to 2033, the market will accelerate at 10% CAGR, propelled by cancer prevalence, interchangeability, and delivery innovations. By 2025, amid ongoing biosimilar uptake, market share could reach 85% as per recent reports, with values nearing $1.8-1.84 billion. Future trends include oral formulations and AI-driven development, aligning with sustainability. Challenges like litigation will persist, but opportunities in emerging markets and partnerships will sustain growth.

Browse for A Report:https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market

Pegfilgrastim Biosimilar Industry News:

Recent developments highlight the pegfilgrastim biosimilar market's dynamism. In Q1 2025, Samsung Bioepis reported pegfilgrastim biosimilars achieving 85% market share in year 7, with average selling prices dropping significantly. Coherent Market Insights projected 2025 market size at $1.84 billion, growing to $3.39 billion by 2032 at 9.1% CAGR. In July 2025, reports noted challenges for some brands amid competition, with Amneal and Kashiv advancing related biosimilars. Biosimilars like pegfilgrastim saw 95% ASP declines since entry, per July 2025 analyses. These trends reflect increasing adoption, price erosion, and innovation focus.

Explore More Related Studies Published by Fact.MR Research:

Shaped Liquid Cartons Market- https://www.factmr.com/report/4183/shaped-liquid-cartons-market
Insulated Drinkware Market- https://www.factmr.com/report/4327/insulated-drinkware-market
Laser Hair Removal Market- https://www.factmr.com/report/laser-hair-removal-market
Face Cream Market- https://www.factmr.com/report/face-cream-market
Shoe Dryer Market- https://www.factmr.com/report/shoe-dryer-market
Sunless Tanners Market- https://www.factmr.com/report/sunless-tanners-market
Soundproof Curtains Market- https://www.factmr.com/report/soundproof-curtains-market
Driving Apparel Market- https://www.factmr.com/report/driving-apparel-market
Mineral Cosmetics Market- https://www.factmr.com/report/mineral-cosmetics-market
Aesthetic Lasers Market- https://www.factmr.com/report/aesthetic-lasers-market

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of Fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.